P16 SSB-positive renal cell carcinoma and anti-PD1-induced Sjögren’s syndrome : a key to understand the link between immune-related adverse events and antitumoral activity?

BJMO - 2021, issue 3, march 2021

Dan Truc Nguyen , Stéphane Holbrecht , Soizic Garaud

Introduction: Immune checkpoint inhibitors (ICI) are becoming a cornerstone of therapies for many cancers. However, a new class of side effects has emerged, namely immune-related adverse events (irAEs). Many studies have suggested a potential relationship between irAEs and benefit of ICI, but little is known about the mechanisms underlying toxicity and antitumor efficacy.

Read more